- Report
- May 2024
- 135 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 132 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- March 2025
- 184 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- February 2025
- 185 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- September 2024
- 183 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Clinical Trials
- April 2025
- 550 Pages
Global
From €4551EUR$5,000USD£3,865GBP
- Report
- April 2025
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Clinical Trials
- April 2025
- 150 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 230 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €4551EUR$5,000USD£3,865GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more